RESUMEN

El desarrollo de la terapia fotodinámica (PDT) nos permite aplicar un nuevo método para tratamiento local en cáncer esofágico, pulmonar y otras malignidades en la piel, cabeza y cuello. La terapia fotodinámica incluye un agente fotosensible (photofrin), el cual cuando se expone a una luz de longitud de onda apropiada (láser), da lugar a radicales de oxígeno tóxicos que resultan en muerte celular. Este método es técnicamente fácil de aplicar, con anestesia local o general y disminuye el riesgo de complicaciones.

PALABRAS CLAVE

Terapia fotodinámica, láser, photofrin.

REFERENCIAS

1. Raab O. Uber die wirkung fluoreszierenden stoffen. Infusoria Z Biol 1900; 39: 524.

2. Jesionek A, Tappeiner VH. Zur behandlung der huatcarcinomit mit fluorescierenden stoffen. Muench Med Wochneshr 1903; 47: 2042.

3. Hausman W. Die sensibilisierende wirkung deshematoporphyrins. Biochem Z 1911; 30: 276.

4. Lipson RL, Baldes EJ. The photodynamic properties of a particular hematoporphyrin derivative. Arch Dermatol 1960; 82: 508-516.

5. Gray M, Lipson RI, Macek JVS et al. Use of hematoporphyrin derivative in detection and management of cervical cancer. Am J Obstet Gynecol 1967; 9: 766-771.

6. Gregorie HB Jr, Horger EO, Ward JL et al. Hematoporphyrin-derivative fluorescense in malignant neoplasms. Ann Surg 1968; 167: 820-828.

7. Lipson RL, Baldes EJ, Gray MJ. Hematoporphyrin derivative for detection and management of cancer. Cancer 1967; 20: 2254-2257.

8. Lipson RL, Baldes EJ, Olsen AM. The use of a derivative of hematoporphyrin in tumor detection. J Natl Cancer Inst 1961; 26: 1-11.

9. Lipson RI, Gray MJ, Baldes EJ. Hematoporphyrin derivative for detection and management of cancer. In: Proceedings of the 9th International Cancer Congress, Tokyo, Japan 1966: 393.

10. Dougherty TJ. Grindley GE, Fiel R et al. Photoradiation therapy II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst 1975; 55: 115-121.

11. Dougherty TJ. Photosensitizers. Therapy and detection of malignant tumors. Photochem Photobiol 1987; 45: 874-889.

12. Dougherty TJ, Potter WR, Weishaupt KR. The structure of the active component of hematoporphyrin derivative. In: Doiron DR, Gomer CJ (eds). Porphyrin localization and treatment of tumors. New York: Alan R Liss 1984: 301.

13. Bugelski PH, Porter CW, Dougherty TJ. Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. Cancer Res 1981; 41: 4606-4612.

14. Selman SH, Kreimer-Birnbaum M, Klauning JE et al. Blood flow in transplantable bladder tumors treated with hematoporphyrin derivative and light. Cancer Res 1984; 44: 1924-1927.

15. Star WM, Marijinissen HP, Van den Berg-Blok AE et al. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res 1986; 46: 2532-2540.

16. Barel A, Jori G, Perin A et al. Role of high, low and very low-density lipoproteins in the transport and tumor-delivery of hematoporphyrin in vivo. Cancer Lett 1986; 32: 145-150.

17. Bellnier DA, Henderson BW. Determinants for photodynamic tissue destruction. In: Henderson BW, Dougherty TJ (eds). Photodynamic Therapy. New York: Marcel Dekker 1992: 117.

18. Jori G, Tomio L, Reddi E et al. Preferential delivery of liposome-incorporated porphyrins to neoplastic cells in tumour-bearing rats. Br J Cancer 1983; 48: 307-309.

19. Pass HI. Photodynamic therapy for lung cancer. Chest Surg Clin North Am 1991; 1: 135-151.

20. Figgie FHJ, Weiland GS, Manganiello LOJ. Cancer detection and therapy. Affinity of neoplastic embryonic and traumatized tissue for porphyrins and metallo-porphyrins. Proc Soc Exp Biol Med 1948; 68: 640-641.

21. Gomer CJ, Dougherty TJ. Determination of [3H] and [14C] hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res 1979; 39: 146-151.

22. Kaye AH, Morstyn G, Ashcroft RG. Uptake and retention of hematoporphyrin derivative in an in vivo/in vitro model of cerebral glioma. Neurosurgery 1985; 17: 883-890.

23. Kessel D. Effects of photoactivated porphyrins at the cell surface of leukemia L 1210 cells. Biochemistry 1977; 16: 3443-3449.

24. Cortese DA, Kinsey JH, Woolner LB et al. Hematoporphyrin derivative in the detection of radiographically occult lung cancer. Am Rev Respir Dis 1982, 126: 1087-1088.

25. Tochner Z, Mitchell JB, Smith P et al. Photodynamic therapy of ascites tumors within the peritoneal cavity. Br J Cancer 1986; 53: 733-736.

26. Lee S, Forbes IJ, Betts WH. Oxigen dependency of photocytotoxicity with haematoporphyrin derivative. Photochem Photobiol 1984; 39: 631-634.

27. Mitchell JB, McPherson S, DeGraff W et al. Oxygen dependence of hematoporphyrin derivative-induced photoinactivation of chinese hamster cells. Cancer Res 1985; 45: 2008-2011.

28. Jamieson CH, McDonald WN, Levy JG. Preferential uptake of benzoporphyrin derivative by leukemic versus normal cells. Leuk Res 1990; 14: 209-219.

29. Pope AJ, Masters W, Macrobert AJ. The photodynamic effect of a pulsed dye laser on human bladder carcinoma cells in vitro. Urol Res 1990; 18: 267-270.

30. Andreoni A, Cubeddu R, DeSilvestri S et al. Effects of laser irradiation on hematoporphyrin-treated normal transformed thyroid cells in culture. Cancer Res 1983; 43: 2076-2080.

31. Borrelli MJ, Wong RSL, Dewey WC. A direct correlation between hyperthermia induced bleeding and survival in synchronous G, CHO cells. J Cell Physiol 1986; 126: 181-190.

32. Volden G, Christensen T, Moan J. Photodynamic membrane damage of hematoporphyrin in derivative treated NHIK 3025 cell in vitro. Photobiochem Photobiophys 1981; 3: 105.

33. Hilf R, Murant RS, Narayanan U et al. Hematoporphyrin derivative-induced photosensitivity of mitochondrial succinate dehydrogenase and selected cytosolic enzymes of R3230AC mammary adenocarcinomas of rats. Cancer Res 1984; 44: 1483-1488.

34. Wieman TJ, Mang TS, Fingar VS et al. Effect of photodynamic therapy on blood flow in normal and tumor vessels. Surgery 1988; 104: 512-517.

35. Fingar VH, Wieman TJ, Doak KW. Role of thromboxane and prostacycline release on phothodynamic therapy-induced tumor destruction. Cancer Res 1990; 50: 2599-2603.

36. Dodd NJ, Moore JV, Poppitt DG et al. In vivo magnetic resonance imaging of the effects of photodynamic therapy. Br J Cancer 1989; 60: 164-167.

37. Mattiello J, Evelhoch JL, Brown E et al. Effect of photodynamic therapy on RIF-I tumor metabolism and blood flow examined by 31 P and 2H NMR spectroscopy. NMR Biomed 1990; 3: 64-67.

38. Pass HI. Photodynamic therapy in oncology. Mechanisms and clinical use. J Natl Cancer Inst 1993; 85: 443-456.

39. Heier SK. Photodynamic therapy for esophageal malignancies. In: Barkin JS, O’Phelan CA (eds). Advanced therapeutic endoscopy, 2nd ed. New York: Raven Press 1994: 57-65.

40. Marcon NE. Photodynamic therapy and cancer of the esophagus. Semin Oncol 1994; 21 (suppl 15): 20-23.

41. McCaughan JS Jr. Photodynamic therapy of endobronchial and esophageal tumors, an overview. J Clin Laser Med Surg 1996; 14: 223-233.

42. Furuse K, Fukuoka M, Kato H et al. A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. J Clin Oncol 1993; 11: 1852-1857.

43. Overholt BF, Panjehpour M. Photodynamic therapy for Barrett’s esophagus: clinical update. Am J Gastroenterol 1996, 91: 1719-1789.

44. Pass HI. Photodynamic therapy in oncology. Mechanisms and clinical use. J Natl Cancer Inst 1993; 85: 443-456.